This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a ...

In patients enrolled in the phase 1b portion of the KRYSTAL-1 trial who received adagrasib, the intracranial objective response rate was 32%. Treatment with pembrolizumab monotherapy demonstrated the ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...

Although pembrolizumab is approved for deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) tumors regardless of histology, there is a paucity of data to support its effectiveness ...

This emphasizes a critical issue as pembrolizumab is increasingly being used in early TNBC and could have long-term survivorship implications. Supported in part by The University of Texas MD Anderson ...

Checkpoint inhibitors are a type of immunotherapy. These drugs block different proteins called checkpoint proteins that stop the immune system from attacking the cancer cells. They are a treatment for ...

Mirati – which is expecting a verdict on adagrasib from the FDA in December - also said the disease control rate was 80% with adagrasib, while the median duration of response came in at 8.5 ...